By Denny Jacob
Regenxbio shares surged 20% after disclosing new, positive efficacy and safety data of its Duchenne muscular dystrophy treatment.
Shares were recently trading around $11.55. The stock is down 46% on the year.
The clinical-stage biotechnology company said the Phase 1/2 portion of its ongoing trial on RGX-202 found that all five participants across both dosage levels demonstrated evidence of positively impacting disease trajectory.
Regenxbio noted the trial has expanded into a multicenter, open-label pivotal Phase 1/2/3 trial of the treatment that is expected to support a biologics license application submission using the accelerated approval pathway in 2026.
"The initiation of our pivotal trial and newly released positive functional data are exciting milestones," said Chief Executive Curran Simpson.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 18, 2024 09:09 ET (14:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。